Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H14N2O3 |
Molecular Weight | 198.2191 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(CC)C(=O)NC(=O)N(C)C1=O
InChI
InChIKey=FWJKNZONDWOGMI-UHFFFAOYSA-N
InChI=1S/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14)
Molecular Formula | C9H14N2O3 |
Molecular Weight | 198.2191 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/209272 |
10.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | GEMONIL Approved UseLong-acting barbiturate that is demethylated to barbital in the liver; has broad-spectrum anticonvulsant action, but used mainly to treat myoclonic spasms in infants. |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8638929/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8638929/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8638929/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8638929/ |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Evaluation of pyridine-3-carboxylic acid as a drug carrier by utilizing multivariate methods, structure property correlations, and pattern recognition techniques. | 2004 |
|
A categorical structure-activity relationship analysis of the developmental toxicity of antithyroid drugs. | 2009 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/13902356
Metharbital is administered orally. Effective dose, causing a reduction in seizure score by 225, is 110 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/209272
The binding of [3H]DHP (dihydropicrotoainin) to rat brain membrane fragments was measured by a centrifugation assay. Assay condition involved incubating 1-3 mg of protein at 0° for 15 min with 63 nM [3H]DHP with or without a given concentration of barbiturate in a total incubation medium of 2 ml. Following incubation, the vials were centrifuged, supernatant discarded, pellets rapidly rinsed, solubilized and prepared for counting as previously described (26) . Specific binding was obtained by subtracting from the total radioactivity in the pellet the background, i .e . the amount not displaced by high concentrations (0.1 mM) of unlabeled DHP. Metharbital inhibits binding of [3H]DHP to GABAA receptor with IC50 of 10 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:33:36 GMT 2023
by
admin
on
Sat Dec 16 17:33:36 GMT 2023
|
Record UNII |
02OS7K758T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67084
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
||
|
WHO-VATC |
QN03AA30
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
||
|
WHO-ATC |
N03AA30
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
METHARBITAL
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
C084822
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
m7303
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000081209
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
7230
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
6825
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID6023280
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
2
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
200-011-2
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
1740
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
DB00463
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
02OS7K758T
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
50-11-3
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
CHEMBL450
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
4099
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
C66113
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
SUB08841MIG
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY | |||
|
27156
Created by
admin on Sat Dec 16 17:33:36 GMT 2023 , Edited by admin on Sat Dec 16 17:33:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |